title: VEGF-A and PDGF-BB--angiogenic factors and the stage of diabetic foot syndrome advancement.
abstract: BACKGROUND
  In patients with diabetic foot syndrome (DFS), an inadequate angiogenic response is observed. The aim of this study was to evaluate the concentrations of VEGF-A, PDGF-BB, sVEGF-R2 and sVEGF-R1 in patients with diabetes-complicated diabetic foot syndrome and analyse them using selected clinical data.
  
  
  METHODS
  Forty seven diabetic patients, 25 women mean age 63 and 20 men mean age 60.5, with diabetic foot syndrome (DFS) were enrolled in the experimental group. To evaluate angiogenesis factors depending on Wagner grade, the subjects were divided into three subgroups: I - patients with 0 Wagner grade (n = 14); II - patients with 1,2,3 Wagner grades (n = 15); and III - patients with 4,5 Wagner grades (n = 18). The control group consisted of 20 healthy volunteers. The material for research was blood.
  
  
  RESULTS
  Significantly higher levels of VEGF-A and PDGF-BB in the DFS cases compared to controls were observed (VEGF-A p = 0.000001; PDGF-BB p = 0.000051). Analysis of angiogenic parameters according to the stage of diabetic foot syndrome advancement showed higher VEGF-A level (I: p = 0.000867; II: p = 0.001827; III: p = 0.000024) and PDGF-BB (respectively p = 0.004113, p = 0.004224, p = 0.002480) in all the subgroups. Decreased sVEGF-R2 concentrations were observed in the I (p = 0.054) subgroup and the III (p = 0.03524) subgroup. In this study, a strong positive correlation between VEGF-A and PDGF-BB was observed (R = 0.66; p = 0.000001).
  
  
  CONCLUSIONS
  Our study revealed that proangiogenic factor levels were increased in DFS. This is associated with lower limb ischaemia and hypoxic conditions. The stage of diabetic foot syndrome advancement influenced VEGF-A and PDGF-BB concentrations.
authors.affiliation: ewelina.drela@wp.pl.
authors.forename: Ewelina
authors.initials: E
authors.lastname: Drela
authors.forename: Arleta
authors.initials: A
authors.lastname: Kulwas
authors.forename: Wiesław
authors.initials: W
authors.lastname: Jundziłł
authors.forename: Barbara
authors.initials: B
authors.lastname: Góralczyk
authors.forename: Joanna
authors.initials: J
authors.lastname: Boinska
authors.forename: Wanda
authors.initials: W
authors.lastname: Drewniak
authors.forename: Grażyna
authors.initials: G
authors.lastname: Gadomska
authors.forename: Danuta
authors.initials: D
authors.lastname: Rość
mesh_terms: D000368:Aged; D000077214:Becaplermin; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D017719:Diabetic Foot / Q000097:blood* / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020574:Proto-Oncogene Proteins c-sis / Q000097:blood*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000097:blood*
chemical_list: D015415:Biomarkers; D020574:Proto-Oncogene Proteins c-sis; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000077214:Becaplermin; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2